IRIS
AGHEMO, Alessio Michele Goffredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.213
EU - Europa 1.613
AS - Asia 905
AF - Africa 290
OC - Oceania 12
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 7
Totale 12.048
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.119
SG - Singapore 504
FI - Finlandia 431
IE - Irlanda 305
NG - Nigeria 270
CN - Cina 234
DE - Germania 165
IT - Italia 152
FR - Francia 148
NL - Olanda 102
CA - Canada 93
SE - Svezia 92
GB - Regno Unito 63
IL - Israele 42
RU - Federazione Russa 41
TR - Turchia 40
IN - India 38
BE - Belgio 34
EG - Egitto 16
MK - Macedonia 16
IR - Iran 14
UA - Ucraina 11
HK - Hong Kong 10
AU - Australia 9
CZ - Repubblica Ceca 8
PH - Filippine 8
RO - Romania 8
ES - Italia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GR - Grecia 6
CH - Svizzera 4
JP - Giappone 4
PL - Polonia 4
CL - Cile 3
ET - Etiopia 3
MD - Moldavia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
TW - Taiwan 3
AL - Albania 2
BD - Bangladesh 2
BG - Bulgaria 2
BR - Brasile 2
RS - Serbia 2
SA - Arabia Saudita 2
AT - Austria 1
BO - Bolivia 1
CO - Colombia 1
DK - Danimarca 1
EU - Europa 1
ID - Indonesia 1
IM - Isola di Man 1
IS - Islanda 1
PA - Panama 1
UG - Uganda 1
VE - Venezuela 1
Totale 12.048
Salva come PNG Salva come JPEG
Città #
Chandler 1.911
Wilmington 1.646
San Mateo 689
Ann Arbor 530
Helsinki 431
Boardman 371
Singapore 327
Leawood 310
Dublin 303
New York 301
Lawrence 287
Princeton 287
Benin City 270
Ashburn 266
Shanghai 225
Paris 148
Woodbridge 136
Fairfield 132
Amsterdam 100
Toronto 85
London 53
Milan 53
Seattle 53
San Diego 49
Kocaeli 39
Brussels 34
Norwalk 33
Falls Church 27
Moscow 27
Santa Clara 23
Pune 22
Phoenix 17
Cambridge 15
Los Angeles 15
Monmouth Junction 15
Rome 14
Frankfurt am Main 12
Asyut 11
Des Moines 11
Redmond 11
Redwood City 11
Andover 10
Clearwater 10
Brno 8
Falkenstein 8
Houston 8
Skopje 8
Hanover 7
Ardabil 6
Sacramento 6
Tappahannock 6
Bari 5
Bitola 5
Henderson 5
Abbiategrasso 4
Berlin 4
Winnipeg 4
Addis Ababa 3
Beijing 3
Chisinau 3
Dallas 3
Florence 3
Genoa 3
Gunzenhausen 3
Hangzhou 3
Olongapo City 3
Prilep 3
Taipei 3
Adliswil 2
Apo 2
Athens 2
Auckland 2
Aversa 2
Cairo 2
Cinisello Balsamo 2
Cusano Milanino 2
Edmonton 2
Gdansk 2
Kafr ash Shaykh 2
Kemerovo 2
Kyiv 2
Las Pinas 2
Las Vegas 2
Leipzig 2
Manila 2
Monza 2
Novokuznetsk 2
Penrith 2
Perth 2
Raleigh 2
Sale Marasino 2
St Petersburg 2
Torino 2
Venegono Superiore 2
Washington 2
Aachen 1
Al Mansurah 1
Alexandria 1
Augusta 1
Ballymena 1
Totale 9.496
Salva come PNG Salva come JPEG
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 123
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 84
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 83
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 68
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 68
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 68
Real life experiences in HCV management in 2018 67
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 67
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 66
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 64
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 63
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 63
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 62
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 62
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 62
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 62
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 62
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 61
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 61
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 60
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 59
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 59
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 59
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 59
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 59
REGULATION OF VASOPRESSIN SECRETION AFTER ADMINISTRATION OF SODIUM-NITROPRUSSIDE IN HYPERTENSIVES 59
High mortality in COVID-19 patients with mild respiratory disease 59
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 59
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 59
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 58
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 58
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 58
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 58
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 58
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 58
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 58
EASL Recommendations on Treatment of Hepatitis C 2014 57
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 57
Hepatitis C treatment in patients with kidney disease 57
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 57
OSMOREGULATION OF VASOPRESSIN DURING ACUTE LOWERING OF ARTERIAL-PRESSURE BY CLONIDINE IN MODERATE HYPERTENSION 57
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 57
Estimating HCV disease burden - volume 3 (editorial) 56
Hepatorenal Syndrome and Novel Advances in its Management 56
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals 56
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 56
COINCIDENCE OF CALCITONIN-GENE-RELATED PEPTIDE IMMUNOREACTIVITY AND TERMINAL FIELDS OF EFFERENTS FROM THE CARDIOVASCULAR PORTION OF THE FASTIGIAL NUCLEUS - PRELIMINARY-REPORT 56
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 56
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 56
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 56
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? 55
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 55
Chronic hepatitis C: standard of care and perspective 54
Will the benefits of treatment for chronic hepatitis C be retained in the interferon-free era? 54
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 54
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 54
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis 53
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 53
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 53
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 53
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 53
From current status to optimization of HCV treatment: Recommendations from an expert panel 53
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 52
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 52
The Role Of Serum Alphafetoprotein Determination In HCV-Cirrhosis After Antiviral Treatment 52
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure 52
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 52
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 52
Prevalence and Clinical Impact of Hepatitis E Virus in Immunosuppressed Patient after Liver Transplantation 52
Interferon-free oral therapy for hepatitis C : "faraway, so close!" 51
Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. 51
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 51
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 51
Treatment of chronic hepatitis C: can complexity pave the way towards elimination? 50
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 50
Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario 50
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1 50
Safety of vedolizumab in liver transplant recipients: A systematic review 50
Impaired response to interferon-alpha 2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection 49
Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage 49
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 49
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 49
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 48
Reply to: "The "pegylated" story continues - Perhaps because both ends (alpha 2a and alpha 2b) are true?" 48
Daclatasvir for the treatment of chronic hepatitis C 48
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 48
Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report 48
Role of liver biopsy in hepatocellular carcinoma 48
Mediterranean diet and NAFLD: what we know and questions that still need to be answered. 47
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 47
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 47
Genotype dependent pattern of peginterferon alfa-2b/ribavirin treatment failure in hepatiti sC virus infected patients with cirrhosis : a single center study of 471 naive patients 47
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 47
Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients 47
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 47
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 46
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 46
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 46
Second wave anti-HCV protease inhibitors: too little too late? 45
New horizons in hepatitis C antiviral therapy with direct-acting antivirals 45
Totale 5.606
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.725
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.725
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011 0 0 0 0 0 0 0 0 0 0 0 11
2020/20213.072 22 30 27 16 8 964 481 213 528 399 13 371
2021/20221.690 79 18 59 359 20 21 77 221 121 197 405 113
2022/20234.725 673 210 456 559 429 407 7 414 873 361 271 65
2023/20242.646 179 260 545 127 102 414 144 153 37 46 248 391
2024/202591 91 0 0 0 0 0 0 0 0 0 0 0
Totale 12.235